No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 29 of the 35 quarters in the window, leaving 6 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 36
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:23:43.718Z. Latest historical point 2023-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Solid Biosciences Inc. (SLDB) stock was $6.92 as of Oct 6, 2026, 4:00 PM EDT, down 1.98% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +19.6% · 3-year avg +44.9%/yr · 5-year avg -27.5%/yr
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD).
Biotechnology · Charlestown, MA
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
-0.37
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.38
vs Estimate
$-0.46
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SLDB | $681.27M | $6.92 | -1.98% | +19.56% | -27.50% | N/A | N/A |
| 2VSTM | $681.02M | $7.75 | -3.13% | -8.01% | -25.22% | -7.09% | vs SLDB |
| 3AVR | $685.49M | $7.05 | -6.62% | +74.71% | N/A | N/A | vs SLDB |
| 4MDXG | $673.41M | $4.62 | +1.54% | -36.75% | -4.94% | -6.46% | vs SLDB |
| 5OLMA | $691.79M | $7.92 | -4.00% | -25.57% | -21.50% | N/A | vs SLDB |
| 6FTH | $693.19M | $26.89 | -0.77% | +182.36% | -31.75% | N/A | vs SLDB |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 13 analysts
Average Price Target
$18.62
+169.0% upside
Low
$11.00
Current
$6.92
High
$26.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.42 | $-0.41 | $-0.38 | 8 |
| Quarter ending Dec 2026 | $-0.43 | $-0.42 | $-0.39 | 8 |
| Quarter ending Mar 2027 | $-0.43 | $-0.43 | $-0.43 | 3 |
| Quarter ending Jun 2027 | $-0.43 | $-0.43 | $-0.43 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.03 | $-1.75 | $-1.63 | 10 |
| FY 2027 | $-2.38 | $-1.69 | $-1.36 | 10 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.68M | $3.68M | $3.68M | 11 |
| FY 2027 | $11.47M | $11.47M | $11.47M | 8 |
